Abstract |
The elevated estradiol/ testosterone (E2/T) ratio had been proved to be a risk factor for coronary heart disease (CHD) in elderly men. We conducted a randomized placebo controlled crossover study on the effects of a new androgenic preparation " Andriol" in 62 elderly men with CHD over a period of 2.5 months. The results showed significant differences between Andriol- and placebo-treated groups at the end of this period: in the former, serum T level was elevated significantly (P < 0.001), E2 level was unchanged (P > 0.05), E2/T ratio was reduced (P < 0.05), angina pectoris (AP) was relieved (total effective rate, 77.4%), and myocardial ischemia in ECG and Holter recordings were improved (total effective rate, respectively 68.8% and 75%). Doppler echocardiography showed that 12 parameters of cardiac function were unchanged in both groups. No obvious side effect was found in those who took Andriol.
|
Authors | S Z Wu, X Z Weng |
Journal | Chinese medical journal
(Chin Med J (Engl))
Vol. 106
Issue 6
Pg. 415-8
(Jun 1993)
ISSN: 0366-6999 [Print] China |
PMID | 8222891
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Testosterone
- Estradiol
- testosterone undecanoate
|
Topics |
- Aged
- Angina Pectoris
(blood, drug therapy)
- Coronary Disease
(blood, drug therapy, physiopathology)
- Estradiol
(blood)
- Heart
(physiopathology)
- Humans
- Male
- Middle Aged
- Testosterone
(analogs & derivatives, blood, therapeutic use)
|